We still have EyesOn Clinical Asset updates. This week we cover GSK's FDA approval for Jideytro, Royalty's ATTR deal, plus the Sanofi and Roche portfolio adjustments that include discontinuation of some assets.

We've had EyesOn recent clinical trial updates. Otsuka Pharma received approval for their ADHD therapy, Simtriyo, potentially a game changer for patients aged 6 and older. Meanwhile, Sanofi has stopped development of SAR445399, in bronchiectasis patients without cystic fibrosis as part of ther Portfolio re-alignment efforts.

Three recent clinical updates illustrate the opportunities and challenges facing next-generation oncology therapies. ADC Therapeutics reported positive efficacy data for Zynlonta...

The week we've had Eyes on the Ocular Therapeutix phase 3 SOL-1 data showing superiority over Eylea in wet AMD. The trial showed improved visual acuity preservation, The program could introduce the first tyrosine kinase inhibitor therapy for wet AMD however, investors reacted cautiously to the news.

The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and

The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.